{"filing":{"accession_number":"0001214659-26-008398","cik":"0001643918","ticker":"BDRX","company_name":"Biodexa Pharmaceuticals Plc","form":"6-K","filing_date":"2026-07-09","report_date":null,"primary_document":"w792616k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926008398/w792616k.htm"},"events":[{"id":16841,"run_id":15068,"accession_number":"0001214659-26-008398","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Biodexa Pharmaceuticals PLC is holding an Extraordinary General Meeting on July 29, 2026, to approve four material resolutions: (1) a 10,000-to-1 share consolidation with creation of deferred shares; (2) authorization to allot up to £25,000,000 in equity securities; (3) disapplication of pre-emption rights for cash issuances; and (4) adoption of new articles of association. These structural and constitutional changes materially affect the company's capital structure and future financing flexibility.","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-09","form":"6-K","submitted_at":null,"items":[{"id":15060,"accession_number":"0001214659-26-008398","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This is a Notice of General Meeting for Biodexa Pharmaceuticals PLC containing four resolutions: (1) a share capital reorganization consolidating 10,000 existing ordinary shares into 1 consolidated share and creating deferred shares; (2) authorization to allot up to £25,000,000 in equity securities; (3) disapplication of pre-emption rights for cash issuances; and (4) adoption of new articles of association. These are governance matters—shareholder voting on capital structure, board authorities, and constitutional amendments—that would materially affect investor assessment of the company's capital structure and future financing flexibility. The share consolidation and deferred share creation are particularly material structural changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15061,"accession_number":"0001214659-26-008398","item_number":"EX-99.2","item_title":"ex99_2.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is a Form of Proxy and Attendance Card for a General Meeting scheduled for 29 July 2026. It is a routine administrative governance document enabling shareholders to appoint proxies and attend the meeting. While the meeting will address resolutions including a Share Capital Reorganisation and new articles of association, the proxy form itself is procedural documentation, not disclosure of the substantive outcomes or decisions. This is a standard shareholder meeting notice and proxy mechanism, not a material event disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15062,"accession_number":"0001214659-26-008398","item_number":"EX-99.3","item_title":"ex99_3.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Voting Instruction Card for an Extraordinary General Meeting (EGM) scheduled for July 29, 2026, containing four resolutions: (1) a 10,000-to-1 share consolidation followed by subdivision into ordinary and deferred shares; (2) authorization for directors to allot equity securities up to £25 million; (3) disapplication of pre-emption rights for cash allotments; and (4) adoption of new articles of association. While this is technically a voting solicitation document rather than a results announcement, it discloses material shareholder actions (capital restructuring, equity authorization, and articles amendment) that would be classified as shareholder-vote matters. The document is dated July 9, 2026, with voting deadline July 23, 2026, and meeting date July 29, 2026—the vote results have not yet occurred. However, the exhibit furnishes the resolutions themselves, which are material governance and capital events requiring shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15060,"accession_number":"0001214659-26-008398","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This is a Notice of General Meeting for Biodexa Pharmaceuticals PLC containing four resolutions: (1) a share capital reorganization consolidating 10,000 existing ordinary shares into 1 consolidated share and creating deferred shares; (2) authorization to allot up to £25,000,000 in equity securities; (3) disapplication of pre-emption rights for cash issuances; and (4) adoption of new articles of association. These are governance matters—shareholder voting on capital structure, board authorities, and constitutional amendments—that would materially affect investor assessment of the company's capital structure and future financing flexibility. The share consolidation and deferred share creation are particularly material structural changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-09"},{"id":15061,"accession_number":"0001214659-26-008398","item_number":"EX-99.2","item_title":"ex99_2.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is a Form of Proxy and Attendance Card for a General Meeting scheduled for 29 July 2026. It is a routine administrative governance document enabling shareholders to appoint proxies and attend the meeting. While the meeting will address resolutions including a Share Capital Reorganisation and new articles of association, the proxy form itself is procedural documentation, not disclosure of the substantive outcomes or decisions. This is a standard shareholder meeting notice and proxy mechanism, not a material event disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-09"},{"id":15062,"accession_number":"0001214659-26-008398","item_number":"EX-99.3","item_title":"ex99_3.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Voting Instruction Card for an Extraordinary General Meeting (EGM) scheduled for July 29, 2026, containing four resolutions: (1) a 10,000-to-1 share consolidation followed by subdivision into ordinary and deferred shares; (2) authorization for directors to allot equity securities up to £25 million; (3) disapplication of pre-emption rights for cash allotments; and (4) adoption of new articles of association. While this is technically a voting solicitation document rather than a results announcement, it discloses material shareholder actions (capital restructuring, equity authorization, and articles amendment) that would be classified as shareholder-vote matters. The document is dated July 9, 2026, with voting deadline July 23, 2026, and meeting date July 29, 2026—the vote results have not yet occurred. However, the exhibit furnishes the resolutions themselves, which are material governance and capital events requiring shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:40:02.135299+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-09"}]}